2025 Communication Labelling 
Pharma Marketing Network
MARCH 31, 2025
Introduction Pharmaceutical marketing is entering a new era in 2025, driven by rapid advancements in technology, evolving patient expectations, and tighter compliance demands. Similarly, patients benefit from communications that resonate with their condition, treatment stage, and lifestyle.
Hospital Pharmacy Europe
FEBRUARY 20, 2025
They suggested that pharmacy-specific interventions should include targeted messaging and informative displays at the point of care, clearer labelling on medications to highlight their environmental impact and better access to pharmacy return schemes for unwanted medicines. 2025 Jan 20;15(1):e088066. doi: 10.1136/bmjopen-2024-088066.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The FDA Law Blog
SEPTEMBER 22, 2024
Corrections and Removals Under 21 CFR Part 806, manufacturers generally need to communicate corrections and removals (i.e., Stage 1 is scheduled to take effect on May 6, 2025. FDA plans to hold its next webinar on September 24, 2024, which will cover the labeling requirements that go into effect in Stage 2.
Pharmaceutical Technology
DECEMBER 22, 2022
The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. However, he did point out that the joint assessment could be a useful way of narrowing down typically broad EMA label content to specific patient populations.
Hospital Pharmacy Europe
MARCH 13, 2025
Timely follow-up after hospital attendance and communication at transfers of care is therefore imperative Identifying patients through targeted searching of primary care databases is expected to be a way to review prescribing and revisit diagnosis. Accessed February 2025]. Accessed February 2025]. Accessed February 2025].
The FDA Law Blog
JULY 7, 2024
The first phaseout milestone is less than a year away; by May 6, 2025 most laboratories will need to demonstrate compliance with Medical Device Reporting (21 C.F.R. § 11] In the context of an LDT, it is unclear what FDA will include within the scope of “labeling” and what types of communications will be considered “claims.”
Hospital Pharmacy Europe
APRIL 14, 2025
However, issues arose due to a lack of PAAP, insufficient communication between or within services and families, failure to recognise child deterioration, and treatment delays. Learnings from the CDOPs showed that allergy symptoms were not always communicated to healthcare professionals. Accessed March 2025]. Childhood asthma.
Expert insights. Personalized for you.
52 
Let's personalize your content